TB-500 vs Thymosin Alpha-1
TB-500 (Thymosin Beta-4 fragment) and Thymosin Alpha-1 are both derived from the thymus gland but serve completely different biological functions. TB-500 is studied for tissue repair, wound healing, and cell migration. Thymosin Alpha-1 is an immunomodulatory peptide studied for immune system enhancement, viral infections, and cancer immunotherapy support.
Despite sharing 'Thymosin' in their names and thymic origin, these peptides have almost no overlap in research applications. This comparison clarifies the distinction.
Similarities
- =Both are derived from thymus gland proteins (thymosin family)
- =Both are synthetic peptides available from research vendors
- =Both are administered via subcutaneous injection in research
- =Both have published research spanning several decades
- =Both are well-tolerated with favorable safety profiles in studies
- =Both are named after the thymus but target completely different pathways
Key Differences
| Aspect | TB-500 | Thymosin Alpha-1 |
|---|---|---|
| Parent Protein | Thymosin Beta-4 (tissue repair protein) | Thymosin Alpha-1 (immune regulatory protein) |
| Primary Function | Tissue repair, wound healing, cell migration | Immune modulation, T-cell maturation, antiviral activity |
| Mechanism | Promotes actin polymerization, angiogenesis, cell migration | Enhances T-cell function, dendritic cell maturation, NK cell activity |
| Research Focus | Injury recovery, cardiac repair, dermal wound healing | Viral hepatitis, immunodeficiency, cancer immunotherapy adjunct |
| Regulatory Status | Research compound only — no approvals | Approved in 35+ countries (as Zadaxin) for hepatitis B/C |
| Clinical Data | Primarily animal studies and preclinical data | Extensive human clinical trials and regulatory approvals |
| Typical Dose | 2-5 mg twice weekly in research protocols | 1.6 mg twice weekly (standard clinical dose) |
Which to Choose for Your Research
Tissue repair / injury recovery research
TB-500TB-500 promotes cell migration, angiogenesis, and tissue repair. It has no significant immunological research applications.
Immune system enhancement research
Thymosin Alpha-1Thymosin Alpha-1 is the clear choice with regulatory approvals in 35+ countries and extensive clinical data on immune enhancement.
Viral infection research
Thymosin Alpha-1Thymosin Alpha-1 has been studied extensively for hepatitis B/C and has shown benefit in various viral infection models. TB-500 has no antiviral research.
Cardiac repair research
TB-500Thymosin Beta-4 (TB-500's parent) has specific cardiac repair research, including studies on reducing fibrosis and improving outcomes after myocardial infarction.
Cancer immunotherapy support research
Thymosin Alpha-1Thymosin Alpha-1 has been studied as an immunotherapy adjunct, enhancing immune response when combined with other cancer treatments. TB-500 is not studied in oncology.
The Verdict
Despite sharing the 'Thymosin' name, TB-500 and Thymosin Alpha-1 are completely different peptides for completely different research. TB-500 is for tissue repair and healing research. Thymosin Alpha-1 is for immune modulation and infectious disease research. There is essentially no overlap in their applications.
Thymosin Alpha-1 has the stronger regulatory and clinical evidence base, with approvals in 35+ countries. TB-500 has less formal clinical data but extensive preclinical research. Choose based entirely on your research focus: healing (TB-500) or immunity (Thymosin Alpha-1).
Frequently Asked Questions
Are TB-500 and Thymosin Alpha-1 related?
Only by name — both are thymosin family peptides originally isolated from the thymus gland. TB-500 is from Thymosin Beta-4 (tissue repair), while Thymosin Alpha-1 is a distinct immune-regulatory peptide. They have completely different sequences, mechanisms, and applications.
Can they be combined?
Since they target completely different systems (tissue repair vs immune modulation), combination use is not standard but could theoretically address both healing and immune function. There is no published data on this specific combination.
Which has better clinical evidence?
Thymosin Alpha-1 has far more clinical evidence, including Phase III trials and regulatory approvals in 35+ countries (as Zadaxin). TB-500's research is primarily preclinical (animal models).
Is Thymosin Alpha-1 still used clinically?
Yes — Thymosin Alpha-1 (Zadaxin) is approved and used clinically in many countries for hepatitis B, hepatitis C, and as an immune adjunct. It received increased attention during COVID-19 for potential immune support.
TB-500
View full compound page with vendor pricing.
Compare 30 products →Thymosin Alpha-1
Immune-modulating peptide used in hepatitis and cancer research....
Compare 21 products →More Comparisons
For research reference only. Not medical advice. Not for human consumption. All compounds discussed are research chemicals.